These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37229608)

  • 1. Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2.
    Verstraete MM; Heinkel F; Li J; Cao S; Tran A; Halverson EC; Gene R; Stangle E; Silva-Moreno B; Arrafi S; Bavananthasivam J; Fung M; Eji-Lasisi M; Masterman S; Xanthoudakis S; Dixit S; Babcook J; Clavette B; Fogg M; Escobar-Cabrera E
    MAbs; 2023; 15(1):2212415. PubMed ID: 37229608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
    Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
    J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection.
    Lu M; Yao W; Li Y; Ma D; Zhang Z; Wang H; Tang X; Wang Y; Li C; Cheng D; Lin H; Yin Y; Zhao J; Zhong G
    Microbiol Spectr; 2023 Aug; 11(4):e0110023. PubMed ID: 37395664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models.
    Urano E; Itoh Y; Suzuki T; Sasaki T; Kishikawa JI; Akamatsu K; Higuchi Y; Sakai Y; Okamura T; Mitoma S; Sugihara F; Takada A; Kimura M; Nakao S; Hirose M; Sasaki T; Koketsu R; Tsuji S; Yanagida S; Shioda T; Hara E; Matoba S; Matsuura Y; Kanda Y; Arase H; Okada M; Takagi J; Kato T; Hoshino A; Yasutomi Y; Saito A; Okamoto T
    Sci Transl Med; 2023 Aug; 15(711):eadi2623. PubMed ID: 37647387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.
    Havranek B; Lindsey GW; Higuchi Y; Itoh Y; Suzuki T; Okamoto T; Hoshino A; Procko E; Islam SM
    Commun Biol; 2023 May; 6(1):513. PubMed ID: 37173421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
    Leach A; Ilca FT; Akbar Z; Ferrari M; Bentley EM; Mattiuzzo G; Onuoha S; Miller A; Ali H; Rabbitts TH
    Antiviral Res; 2021 Oct; 194():105147. PubMed ID: 34375715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo.
    Ikemura N; Taminishi S; Inaba T; Arimori T; Motooka D; Katoh K; Kirita Y; Higuchi Y; Li S; Suzuki T; Itoh Y; Ozaki Y; Nakamura S; Matoba S; Standley DM; Okamoto T; Takagi J; Hoshino A
    Sci Transl Med; 2022 Jun; 14(650):eabn7737. PubMed ID: 35471044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE2-based decoy receptors for SARS coronavirus 2.
    Jing W; Procko E
    Proteins; 2021 Sep; 89(9):1065-1078. PubMed ID: 33973262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
    Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
    Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants.
    Svilenov HL; Bester R; Sacherl J; Absmeier R; Peters C; Protzer U; Brockmeyer C; Buchner J
    Commun Biol; 2022 Nov; 5(1):1237. PubMed ID: 36371561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants.
    Liu J; Mao F; Chen J; Lu S; Qi Y; Sun Y; Fang L; Yeung ML; Liu C; Yu G; Li G; Liu X; Yao Y; Huang P; Hao D; Liu Z; Ding Y; Liu H; Yang F; Chen P; Sa R; Sheng Y; Tian X; Peng R; Li X; Luo J; Cheng Y; Zheng Y; Lin Y; Song R; Jin R; Huang B; Choe H; Farzan M; Yuen KY; Tan W; Peng X; Sui J; Li W
    Nat Commun; 2023 Aug; 14(1):5191. PubMed ID: 37626079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 spike protein variant binding affinity to an angiotensin-converting enzyme 2 fusion glycoproteins.
    Matthews AM; Biel TG; Ortega-Rodriguez U; Falkowski VM; Bush X; Faison T; Xie H; Agarabi C; Rao VA; Ju T
    PLoS One; 2022; 17(12):e0278294. PubMed ID: 36472974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine Learning Guided Design of High-Affinity ACE2 Decoys for SARS-CoV-2 Neutralization.
    Chan MC; Chan KK; Procko E; Shukla D
    J Phys Chem B; 2023 Mar; 127(9):1995-2001. PubMed ID: 36827526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant.
    Zhang H; Hu B; Lv P; Liu Y; Guo M; Wu Z; Zhou K; Dai M; Yu X; Liu Z; Yu B; Xu L; Guo M; Cai K; Li Y
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.
    Ku Z; Xie X; Hinton PR; Liu X; Ye X; Muruato AE; Ng DC; Biswas S; Zou J; Liu Y; Pandya D; Menachery VD; Rahman S; Cao YA; Deng H; Xiong W; Carlin KB; Liu J; Su H; Haanes EJ; Keyt BA; Zhang N; Carroll SF; Shi PY; An Z
    Nature; 2021 Jul; 595(7869):718-723. PubMed ID: 34082438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced binding and inhibition of SARS-CoV-2 by a plant-derived ACE2 protein containing a fused mu tailpiece.
    Lim S; Kwon HJ; Jeong DG; Nie H; Lee S; Ko SR; Lee KS; Ryu YB; Mason HS; Kim HS; Shin AY; Kwon SY
    Biotechnol J; 2024 Jan; 19(1):e2300319. PubMed ID: 37853601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors.
    Alfaleh MA; Zawawi A; Al-Amri SS; Hashem AM
    MAbs; 2022; 14(1):2057832. PubMed ID: 35380919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2.
    Wines BD; Kurtovic L; Trist HM; Esparon S; Lopez E; Chappin K; Chan LJ; Mordant FL; Lee WS; Gherardin NA; Patel SK; Hartley GE; Pymm P; Cooney JP; Beeson JG; Godfrey DI; Burrell LM; van Zelm MC; Wheatley AK; Chung AW; Tham WH; Subbarao K; Kent SJ; Hogarth PM
    Front Immunol; 2022; 13():889372. PubMed ID: 35967361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.